
欧洲冻干注射剂市场预测至 2028 年 – COVID-19 影响和区域分析 – 按包装类型(一次性小瓶、护理点重构和特种包装)、交付类型(预装稀释注射器、单步设备、专有重构设备和多步设备)、适应症(代谢和肿瘤疾病、传染病、自身免疫性疾病等)和最终用户(医院、门诊手术中心、专科诊所等) � �
No. of Pages: 141 | Report Code: BMIRE00027586 | Category: Life Sciences
No. of Pages: 141 | Report Code: BMIRE00027586 | Category: Life Sciences
欧洲冻干注射剂市场预计将从2022年的8.0834亿美元增长到2028年的11.0845亿美元。预计2022年至2028年复合年增长率为5.4%。 ;
对合同研究制造服务的需求不断增加
span>
冷冻干燥或冻干是一种将冰晶升华为蒸气的干燥过程。冻干是一个基于负温度以及产品活性和稳定性的过程。此外,在此过程中,活性成分得到更好的保留,同时限制对产品的任何损害并避免分子的任何降解。因此,冷冻干燥在制药和诊断领域特别受欢迎。冻干注射药物质量的提高和保质期的延长为在产品制造中实施冻干工艺创造了机会。合同制造和研究服务的需求巨大,需要提供冻干注射药物,为最终用户提供高质量的产品。此外,许多制药公司正在重新关注其核心能力,例如研发,导致内部制造能力的剥离,这增加了对制造合同研究和制造服务(CRAM)的需求。此外,CRAM 通过为具有多站点供应策略和备份能力的制药公司提供额外站点,在提供额外能力以减轻供应短缺风险方面发挥着至关重要的作用。此外,冻干注射剂还具有安全运输、延长药品保存期限等诸多优势,越来越多的地区企业采用冻干技术。
市场概览
欧洲冻干注射剂市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。德国在2022年占据市场主导地位。德国拥有发达的医疗保健系统。所有合法的&德国居民有权获得免费的必要医疗帮助,由法定缴费制度资助。所有居民都必须拥有涵盖门诊、住院、医疗健康和处方药的医疗保险。呼吸系统疾病是德国最常见的死亡原因之一,其中包括肺部疾病和癌症。此外,年轻人生活方式的改变导致代谢和自身免疫性疾病的增加,从而刺激了对冻干注射剂的需求。呼吸系统疾病与肺癌一样是常见的死亡原因之一,而心血管疾病的增加进一步加剧了这一问题,心血管疾病约占德国死亡人数的 40%。根据世界卫生组织2020年报告,肺癌是德国人口第三大死因,患病率为癌症总病例的10.3%。另一方面,由于医疗设施发达,传染病发病率上升,德国抗生素种类繁多,导致日常抗生素使用量增加,从而产生了对冻干注射剂的需求。此外,运输成本高、碳足迹增加、保质期长等因素也增加了国内对冻干药品的需求。
< span>
欧洲冻干注射剂市场细分
欧洲冻干注射剂市场根据包装类型、交付类型、适应症、最终用户和国家/地区进行细分。
就交付类型而言,欧洲冻干注射剂市场分为预充稀释剂注射器、单步装置、专有重构装置和多步装置。预充式稀释注射器细分市场在 2022 年占据最大市场份额。
Strategic insights for Europe Lyophilized Injectable involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 808.34 Million |
Market Size by 2028 | US$ 1,108.45 Million |
Global CAGR (2022 - 2028) | 5.4% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 包装类型
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Lyophilized Injectable refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Lyophilized Injectable Market is valued at US$ 808.34 Million in 2022, it is projected to reach US$ 1,108.45 Million by 2028.
As per our report Europe Lyophilized Injectable Market, the market size is valued at US$ 808.34 Million in 2022, projecting it to reach US$ 1,108.45 Million by 2028. This translates to a CAGR of approximately 5.4% during the forecast period.
The Europe Lyophilized Injectable Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Lyophilized Injectable Market report:
The Europe Lyophilized Injectable Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Lyophilized Injectable Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Lyophilized Injectable Market value chain can benefit from the information contained in a comprehensive market report.